Format

Send to

Choose Destination
Cell Stem Cell. 2015 Jul 2;17(1):8-10. doi: 10.1016/j.stem.2015.06.013.

From Dish to Bedside: Lessons Learned While Translating Findings from a Stem Cell Model of Disease to a Clinical Trial.

Author information

1
Regenerative Medicine Discovery Performance Unit, GlaxoSmithKline, Cambridge, MA 02139, USA. Electronic address: john.d.mcneish@gsk.com.
2
Regenerative Medicine Discovery Performance Unit, GlaxoSmithKline, Cambridge, MA 02139, USA.
3
Departments of Neurology and Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
4
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; FM Kirby Neurobiology Center, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
5
Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Howard Hughes Medical Institute and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02139, USA. Electronic address: eggan@mcb.harvard.edu.

Abstract

While iPSCs have created unprecedented opportunities for drug discovery, there remains uncertainty concerning the path to the clinic for candidate therapeutics discovered with their use. Here we share lessons that we learned, and believe are generalizable to similar efforts, while taking a discovery made using iPSCs into a clinical trial.

PMID:
26140603
DOI:
10.1016/j.stem.2015.06.013
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center